initi buy pt fcrn
best class fcrn potent ivig could game
momenta develop anti-fcrn molecul could potenti best
class displac ivig use treat mani diseas ivig market
current suppli constrain requir multi-day infus fcrn
therapi short iv/sc believ potenti take chunk
sale could address remain market multipl readout
drug expect next month
compani two key drug develop could drive upsid
anti-fcrn drug hypersialyl igg product
evalu fcrn landscap deep-div page
conclud momenta like potent fcrn therapi
greatest reduct igg lower dose believ could translat
better efficaci smaller volum iv sc form
believ data two indic third could
increas probabl investor assign franchis clariti also
come sub-cutan version may learn conveni
patient momenta could first class warm autoimmun hemolyt
anemia waiha studi hdfn could allow file
see market opportun model adjust
sale account earli stage estim everi
addit billion sale could worth depend time
believ mnta approach develop molecul fcrn ivig
space uniqu first creat molecul characterist
want other average licens also chose indic
first look biolog may give advantag
hypersialyt igg molecul bn upsid
potenti bn ivig market potent ivig molecul
could address indic fcrn ivig market label
first indic itp fcrn look effect ivig
expect data also easier manufactur vs ivig
valuat risk pt deriv probabl adjust dcf
discount rate appropri risk associ smid-cap biotech
appli probabl account success
posit poc risk includ financ risk clinic trial failur
competit
tr target
moment come momenta time buy
page
page
strh/bull/bearstrh casebul casebear mn adjust peak sale myasthenia gravi mg market mn adjust peak sale myasthenia gravi mg market mn adjust peak sale myasthenia gravi mg market mn adjust peak sale warm autoimmun hemolyt anemia waiha market mn adjust peak sale warm autoimmun hemolyt anemia waiha market mn adjust peak sale warm autoimmun hemolyt anemia waiha market mn adjust peak sale hemolyt diseas fetu newborn hdfn market mn adjust peak sale hemolyt diseas fetu newborn hdfn market mn adjust peak sale hemolyt diseas fetu newborn hdfn market mn adjust peak sale ivig market intial immun thrombocytopen purpura itp market mn adjust peak sale ivig market intial immun thrombocytopen purpura itp market mn adjust peak sale ivig market intial immun thrombocytopen purpura itp market probabilityfair valuepric target inc
pm summari see signific compani best class fcrn effect market big enough
multipl player could hidden gem investor arent valu
strh thesi momenta best class anti-fcrn differenti develop strategi
nipocalimab contend possibl best-in-class anti-fcrn iv/sq drug
possibl potent easier administ ivig autoimmun inflammatori diseas
like momenta expertis fc modif focu rare immune-medi diseas
pay attent momenta anti-fcrn drug hypersialyl ivig product
momenta differenti diseas indic like taken biolog
clinic rational indic select
bn opportun current indic
highli differenti believ contend possibl best-in-class drug
lead like first-to-class warm autoimmun hemolyt anemia waiha
may anti-fcrn drug label pregnant women provid broader label
possibl highest efficaci profil fcrn space
opportun sole fcrn player fetomatern space
bn potenti upsid potenti bn ivig market
differenti advantag immun thrombocytopen purpura itp anti-inflammatori
shorter infus time dose would less drug volum
easier manufactur ivig suppli constantli run
page
momenta focus rare immune-rel diseas pictur view compani
momenta research pipelin focus develop
molecul rare immune-medi diseas
focu molecul involv immunobiolog
target fcrn fcr use sialyl
focu
focu
follow restructur compani octob
momenta decid termin futur
develop new earli stage biosimilar
legaci product momenta retain
commerci partnership sandoz
glatopa gener version copaxon
gener version lovenox
collabor buy gilbert
develop biosimilar eylea
compani report strh research
page
momenta differ competit abil character design molecul
variou indic dont asset technolog creat new one
strh thesi focu
nipocalimab contend possibl best-in-class anti-fcrn iv drug
possibl potent therapi autoimmun inflammatori diseas
collabor
potenti massiv upsid
compani report strh research
page
momenta three key drug develop differ applic
differ fcr
function
use differ
compani report strh research
page
momenta develop anti-fcrn drug
role fcrn body- increas igg half-lif and/or concentr bodi
certain autoimmun diseas patient antibodi self caus variou
current therapi treat mani diseas often initi includ ivig bind fcrn
competit also anti-inflammatori sourc immun
certain diseas issu mainli driven auto-antibodi also involv
current sale global ivig cap manufactur capac
shortag common
evalu differ anti-fcrn want look side effect thought caus
headach volum infus sub-q volume/spe infus caus headach easi
administr less frequent better importantli potenc
think mani investor look issu look efficaci market
opportun sinc competit could mistak
addit mani compani focu take fcrn max efficaci put indic
without think biolog first momenta look biolog indic first
competit auto-antibodi driven pick right dose drug
momenta drug anti-fcrn class develop hous besid ucb
page
see lot catalyst drive share competitor confid
class could drive upsid well market big
strh research compani report
page
phase top-line phase adapt dataucb top-line phase dataimmunov top-line data phase top-line phase vivacity-mg dataalexion initi phase mgphase top-line phase dataphas top-line phase dataalexion initi phase waihaimmunov file ind waihaphas initi phase registr trialucb initi phase trialmomenta poc datamgitpwaihahdfnmyasthenia gravi mg immun thrombocytopen purpura itp hemolyt diseas fetu newborn hdfn warm autoimmun hemolyt anemia waiha inc
conduct fcrn deep dive look biolog differ competitor
compani develop drug seven indic
believ opportun anti-fcrn drug larg enough player differenti carv
nich best-in-class molecul conveni rout administr import
strh research compani report
get know fcrn
page
companydrugdrug classtarget patient populationgmgitppvcidpefgartigimod sc small myasthenia gravi gmg primari immun thrombocytopenia itp pemphigu vulgari pv chronic inflammatori demyelin polyneuropathi cidp hemolyt diseas fetu newborn hdfn grave ophthalmopathi go warm autoimmun hemolyt anemia waiha determin tbd human aglycosylatednipocalimab pharmaceuticalsefgartigimod ivhuman fc sc human inc
next month catalyst rich fcrn space
strh research compani report
page
companydrugdrug classtarget patient top-line phase adapt initi phase registr initi phase phase poc kol event trial design cidpefgartigimod data path top-line data phase top-line data phase top-line data phase file ind initi phase sc small phase sad/mad biomark datawaihaearli initi phase initi phase mgtbdearli initi trial use sc top-line phase top-line phase initi trial top-line phase top-line phase vivacity-mg top-line phase updat sc formulationhuman fc fragmenthuman aglycosylatedalexion pharmaceuticalsmomentaargenximmunovantefgartigimod myasthenia gravi gmg immun thrombocytopen purpura itp pemphigu vulgari pv chronic inflammatori demyelin polyneuropathi cidp hemolyt diseas fetu newborn hdfn grave ophthalmopathi go warm autoimmun hemolyt anemia waiha determin tbd inc
controversi conclus fcrn deep dive
strh research compani report
page
molecul slide headach slide iv vs sc slide igg reduct slide indic slide albumin reduct slide strh take argenx efgartigimod fc sc weekli mliv itp cidp gener fcrn drugstrh take molecul smaller molecul interf albumin binding/serum levelsimmunov sc inject weekli mlsc waiha godose-depend revers asymptomaticcontend possibl best-in-class sc formulationstrh take molecul well-understood reduc unknown risk help affin optimizationalexion pharmaceut proteinunlik low riskassum weekli inferior fcrn drugsalexion pharmaceut everi waihanoneinferior fcrn drugsucb rozanolixizumab weekli hr infusioniv itp cidpsmal decreas notedinferior fcrn drugsstrh take molecul scaffold may correl risk headach momenta nipocalimab monthli waiha hdfndose-depend revers asymptomaticcontend possibl best-in-class iv formulationstrh take molecul bacteri protein sequence/smal molecule/ albumin-bind domain may risk immunogen interf albumin serum level potenti longer half-lif strh take molecul scaffold may correl risk headach strh take molecul well-understood reduc unknown risk allow better optim aglycosly remov effector function make focus fcrn drug inc
pt deriv probabl adjust dcf
use discount rate believ reflect risk smid-cap biotech
appli probabl three market equat adjust sale mg
waiha hdfn account think investor assign valu see
initi data phase await poc data
use typic valu post smaller phase trial mg waiha read hdfn
post posit poc data
figur million dollar except per share data
compani report strh research
page
assumpt sale sale free projectionsgaap ebit stock base depreci work capit capit free valu growth rate valu valu outstand valu per valu per inc
figur million dollar except per share data
compani report strh research
page
incom product oper oper profit itemsoth expens incom incom tax incom ep non-gaap adjust collabor stock-bas stock-bas incom share share share dilut use non-gaap inc
figur million dollar except per share data
compani report strh research
page
balanc asset cash expens current current secur asset long-term liabil accru current current revenu net current long-term stockhold liabil inc
figur million dollar except per share data
compani report strh research
page
flow from/ use oper activ net reconcil net loss net cash provid use depreci compens discount premium invest dispos oper asset liabil collabor expens current long-term current long-term cash provid by/ use oper flow from/ use invest activ purchas properti dispos market maturities/sal market asset invest cash provid by/ use invest flow from/ use financ activ proce exercis atm share issu stock proce public payment cash provid by/ use financ increase/ decreas cash cash cash equival incl restrict cash cash equival incl restrict cash inc
risk valuat
clinic trial failur poor side effect profil addit data come lead asset
two studi proof concept studi believ current share
price success least
financ risk compani cash runway like need rais money soon
could depend market condit
emerg profil fcrn class clinic trial failur argenx mg stock could
pressur howev think momenta fcrn better competit
competit fcrn landscap competit momenta behind vs first gener compound
page
fcrn deep-div momenta fit
page
nipocalimab contend possibl best-in-class anti-fcrn iv drug
strh thesi focu
nipocalimab contend possibl best-in-class anti-fcrn iv drug
possibl potent therapi autoimmun inflammatori diseas
collabor
potenti massiv upsid
page
fcrn increas serum igg half-lif prevent igg degrad detox
blood detox macromolecul indiscrimin digest bulk degrad
bodi need prevent antibodi degrad maintain serum igg level circul
variou macromolecul
digest remov
circul
bodi
digest
circul
vesicl come contact
fcrn receptor
fcrn protect antibodi
degrad bind
level circul
page
anti-fcrn drug caus degrad pathogen antibodiestr autoimmun diseas
varieti autoimmun
fcrn drug design
high affin fcrn
reduc amount free
fcrn pathogen antibodi
macromolecul
pathogen antibodi bound
free fcrn degrad
remov circul
reduct pathogen
antibodi reduct
caus underli
better outcom
strh take infect risk
minim concern fcrn indic
igg believ approv ivig
risk-benefit fcrn indic
patient risk viru reactiv
also properli exclud
page
fcrn drug broad applic possibl address autoimmun diseas
page
categori anti-fcrn could influenc commerci viabil
deep-div analysi anti-fcrn class look sever factor compar drug
type molecule/antibodi could determin side effect profil includ headach effector
headach headach caus molecul infus speed/tim main
side effect seen class far
rout administr volum iv vs subq differ opinion attract
often also volum frequenc either could key market leader
efficaci igg reduct potenc like due affin molecul abil fall
fcrn receptor also molecul less potent may limit maximum volum
administ patient cant dose
choic indic overlap compani go differ set
indic believ might optim other fcrn biolog suggest
clear auto-antibodi compon also look effect drug
albumin reduct compar abil bind albumin potent drug tend reduc
albumin fcrn protect igg albumin albumin maintain blood pressur
drug requir albumin theoret could side effect potent
therapi howev date despit albumin reduct seen symptom
ph bind depend theoret could lead variabl less efficaci
page
up-front conclus anti-fcrn analysi
strh research compani report
page
molecul slide headach slide iv vs sc slide igg reduct slide indic slide albumin reduct slide strh take argenx efgartigimod fc sc weekli mliv itp cidp gener fcrn drugstrh take molecul smaller molecul interf albumin binding/serum levelsimmunov sc inject weekli mlsc waiha godose-depend revers asymptomaticcontend possibl best-in-class sc formulationstrh take molecul well-understood reduc unknown risk help affin optimizationalexion pharmaceut proteinunlik low riskassum weekli inferior fcrn drugsalexion pharmaceut everi waihanoneinferior fcrn drugsucb rozanolixizumab weekli hr infusioniv itp cidpsmal decreas notedinferior fcrn drugsstrh take molecul scaffold may correl risk headach momenta nipocalimab monthli waiha hdfndose-depend revers asymptomaticcontend possibl best-in-class iv formulationstrh take molecul bacteri protein sequence/smal molecule/ albumin-bind domain may risk immunogen interf albumin serum level potenti longer half-lif strh take molecul scaffold may correl risk headach strh take molecul well-understood reduc unknown risk allow better optim aglycosly remov effector function make focus fcrn drug inc
momenta differ optim target fcrn
well-understood
help affin
fcrn modifi
fc fragmentstil
start develop
focu sc formul
effector function
ucb molecul high
rate headach
mani respond vs
fcrn data mg
compani report strh research
acquir
drug consist
may risk
page
conclus think best molecul modifi low effector function
thought caus headach alexion seen higher
frequenc headach origin thought use antibodi would reduc effector
function side effect emerg instead
molecul fc portion modifi reduc sugar
chain reduc effector function see less headach small studi
human mutat fc lack affin therefor potenc requir longer iv
infus volum lead headach well
take momenta immunov best molecular design differ slightli
potenc momenta slightli potent translat commerci dont know yet
page
ph bind affin impact dynam fcrn bind drug properti
antibodi bind fcrn
neutral ph bloodthi allow
releas back
fcrn drug design bind
neutral ph help ensur
fcrn receptor remain
block advanc next time
may come contact
antibodi endosom
look disadvantag ph
antibodi bind fcrn slightli acid ph
endosom prevent
degrad
fcrn drug must also design bind
fcrn slightli acid ph endosom
higher affinityotherwis
caus igg degrad reduc igg
compani report strh research
page
conclus poorer affin ph depend less favor
ph depend make sens us fc fragment antibodi mutat
design increas bind fcrn antibodi normal bind fcrn thu otherwis behav
like normal antibodi also display ph depend also surpris lower
bind affin fcrn drug use antigen-bind domain antibodi bind
fcrn rather fc fragment
antibodi small protein given affin antibodi achiev
surpris high affin fcrn compar drug
immunov privat momenta ucb ucb-bru nr alexion
buy karnauska better bind affin momenta ucb look tightest
page
controversi headaches- immunov sub-q zero momenta best profil mild
believ patient benefit less frequent headach sever frequenc
headach import consider uptak
ivig common advers effect headach
though transient major case mild incid newer ivig product
headach delay onset infus last
believ rate could hurt commerci uptak sever relev though
believ momenta immunov contend best-in-class movement toward sc
formul greatli reduc elimin headach
prophylact treatment antihistamin nsaid corticosteroid alon combin seem
fairli effect
headach usual elimin patient switch subcutan immunoglobulin sciv
caus headach
molecule-specif featur certain scaffold distinguish ucb use
stat key drug headach
ucb highest incid headach mg including- sever drop out
argenx toler rate headach mg like due infus lower rate teen
itp studi could go higher shorten infus time next studi half hour vs
momenta less frequent headach mild revers
immunov observ headach
compani report strh research
page
summari headach profil date
note less headach seen recent itp studi
compani report strh research
page
argenxalexionmomentaucbefgartigimod adinistrationivivivivscsciv infus hr hr hr mgnumber injections/admin frequenc adminonc weeklyonc weeklyonc weeklysingl doseonc weeklyonc weeklyassoci headach sever detectedimmunov momenta pharmaceut inc
subq vs iv controversi summari sub-q landscap
note argenx develop anoth sub-q halozym nr
compani report strh research
page
companyimmunovantargenxucbalexionmomentaalexionanti-fcrn regimensc injectioniv induct follow sc infus given minutessc injectioniv iv sc weekli sc sc scsingl dosemean igg reduct two iv induct dose follow sc dose clinic sc formulationnot clinic sc formul inc
controversi iv versu sc formul sc volum
believ conveni less frequent self-inject subcutan benefit anti-fcrn drug
believ success uptak anti-fcrn drug patient diseas area requir sc
formul sc also less headach seen date
howev diseas less frequent iv dose may make sens look pnh exampl ultomiri everi
month dose attract pushback tnf inject common
immunov argu iv would strong uptak medicar popul
believ volum desir believ momenta immunov possibl
contend await updat momenta
immunov lead expect momenta potent may abl get
lower inject volum believ gotten
immunov requir multipl sub-q inject depend dose look
dose multipl dose momenta question mani dose frequenc
believ argenx dose push math less iv like
look halozym given less efficaci may max
alexion affibodi effect management believ everi week commerci viabl
seen singl dose studi howev molecul
far efficaci sub-q look best immunov lead potent data come
two studi
page
iv versu sc formul also need compar volum time evolv
look sc data argenx follow immunov
compani report strh research
page
anti-fcrn competit landscapecompanydrugdrug classtarget patient preclinicalphas sctbdphase healthi volutn sc phase data path top-line data phase top-line data phase file ind sc small proteintbdphas phase sad/mad biomark datatbdplan phase sc deliveryearli initi trial use sc deliveryargenxhuman fc sc human administrationiv infus timedosenumb admin/monthfrequ adminassoci headach frequencyargenxefgartigimod hr iv go know long actingn/amomentanipocalimab iv get hr mg/kg given sever inject week inject per admin weeklynon detect immunov momenta pharmaceut inc
controversi albumin greatest reduction- date
issu seen
fcrn also protect albumin
degrad direct bind
argenx report albumin level
affect
macromolecul
larg revers
asymptomat larg
concern patient
need take caution
believ albumin drop
larg concern
becom problem
believ may also relat
momenta observ
serum albumin reduct
revers patient
page
summari igg reduct
conclus appear momenta iv greatest igg lower immunov close high dose sub-q
advanc vs momenta sub-q question becom momenta sub-q dose/volum given
slightli potent releas anyth yet
compani report strh research
page
argenxmomentaimmunovantucbefgartigimod weekli hr infus move weeklynaiv weeklysc weekli self injectionsc weekli hr infusionigg/patho ab reductionmg sc weekli volunteersiv sc weekli high dose iv sc dose pv weekli iv sub-optimal nanot indicatednot indicatednot indicatedwaihanot weekli iv nanananot indicateditp indicatednanot indicatednot clinic data shown signific serum igg reduct futur focus develop subcutan formulationsalexion momenta pharmaceut inc
serum igg reduct correl efficaci
page
momenta test singl multipl dose nipocalimab healthi volunt
phase singl ascend dose sad multipl weekli ascend dose studi healthi
page
momenta sad mad studi reduc serum igg iv dose
strh take believ serum igg reduct near biolog limit reduct momenta max
iv volunt
sad mad studi show serum igg reduct full receptor occup
sad max igg reduct day dose igg remain week dose
mad igg reduct slow day initi dose hit max day remain
week initi dose
page
immunov studi reduc igg dose high dose
immunov saw less igg reduct sad studi vs iv saw max igg reduct sc dose
would need dose multipl inject
one caveat- much igg reduct need date correl efficaci
page
argenx say saw igg lower reduct igg average
argenx saw less igg reduct sad iv studi healthi volunt
weekli iv studi saw reduct igg averag appear like
like chart would correct comparison
view support less potent drug
page
alexion never formal shown igg reduct knowledg drug
data think present peg confer april seen data
management say data accord check sad igg reduct seen
accord manag disclos follow
igg reduct weekli dose pv
igg reduct weekli dose waiha
igg reduct weekli dose healthi volunt
view like support less effect drug
page
momenta run nipocalimab gener myasthenia gravi gmg
rituximab label
total us patient mg per million peopl
patient adequ treat steroid acetylcholinesteras inhibitor
symptom mg
page
target fcrn myasthenia gravi make sens
strh take believ anti-fcrn drug well-suit mg abil reduc igg make
attract space
pathogen antibodi mg direct acetylcholin receptor achr igg
less frequent pathogen antibodi direct muscle-specif kinas musk low-dens
like target fcrn simultan reduc igg offer broader patient reach
pathogen igg mg target neuromuscular junction nmj lead loss muscl activ
page
momenta alon mg fcrn compani mg competitor data
strh take would look mg initi clinic valid fcrn space mg lead indic
space fcrn compani run trial mg posit data would help valid drug
argenx ucb data respect
also next year initi data immunov top-line phase data argenx
strh research compani report
page
phase top-line phase adapt dataucb top-line phase dataimmunov top-line data phase top-line phase vivacity-mg dataalexion initi phase mgmg momenta pharmaceut inc
efficaci comparison current mg trial suggest momenta look favor
ucb argenx shown stat sig anti-fcrn drug mg-adl
argenx ucb
stat sig clinic trial correl reduct serum igg line tradit techniqu
aim reduc pathogen igg
momenta data healthi volunt give us confid despit slight data decay seen serum igg
healthi volunt mg patient
tighter rang igg reduct like real meaning
higher serum igg reduct argenx ucb
compani report strh research
page
argenxucbefgartigimod vs pborozanolixizumab vs pbomg-adl respons vs vs vs vs use use defin respond pbo placebo momenta pharmaceut inc
summari trial design competitor
strh research compani report
page
companytrialdesignendpoint inclusionimmunovantphas multi-cent random db pc w/ open label extensionprimari safeti chang igg igg subclass chang baselin level anti-achr-iggmgfa class weekli sub-q week plu option open-label extens week everi weekssecondari mg-adl chang week etc pk/pdqmg score screeningplacebo week plu option open-label extens week everi wksanti-achr antibodi positivemomentaphas vivacity- mulit-cent random db placebo-controlledprimari safeti day chang baselin mg-adl score day week dose singl dose vs placebo ivsecondari mani throughout day wk pregnant/breastfeedingaccept achr musk patient stratifiy achr open label extens studi ivprimari safeti yearextens studysecondari chang mg-adl chang qmg etc yearargenxphas adapt- multi-cent random placebo iv iv vs placebodiagnosi mg w/ muscl weak mg-adl respond achr popul week inc
sinc alreadi posit efficaci data argenx- look first
argenx phase mg trial design
page
sinc alreadi efficaci data argenx- look first
primari endpoint qmg mg-adl establish scale mg
qmg physician-report use ivig trial show reduct point
mg-adl patient-report also use reduct point consid meaning
note compani enrol anti-achr patient patient mostli auto
antibodi antibodi
saw vs reduct qmg day
saw reduct vs mg-adl day
page
qmg mg-adl valid scale competitor detect stat sig qmg
miss stat sig qmg scale argenx ucb could function time sampl size
studi pilot studi small number patient
measur later period could run risk abl detect clinic benefit fcrn
drug pathogen igg level begin rise
data argenx phase trial
page
efgartigimod reduct occur week last ivclin data effiaci safeti inc
curiou argnenx phase adapt studi given havent disclos trial design
chanc trial result mix think read trial
argenx yet reveal phase adapt studi design though design expect releas well
ahead data explan
clinicaltri gov primari endpoint mg-adl assess week although compani said
wait present full week studi
compani note weekli iv dose may possibl may look extend
dose use adapt trial design remind efficaci last longer igg reduct
like may take time auto-antibodi build tissu
believ lack clariti endpoint studi design pose uncertainti relat argenx trial
argenx pivot phase trial miss endpoint think like believ
read-through fcrn trial look forward argenx phase design
page
phase vivacity-mg evalu gener myasthenia gravi gmg
notabl studi believ enrol comer would includ
anti-achr mediat antibodi also anti-musk patient
musk mg patient usual poorer respons acetylcholinesteras inhibitor
page
momenta phase use favor dose monthli
like momenta move
toward monthli dose iv
look develop sc formul
inject administr import
space
compani report strh research
page
argenxmomentaimmunovantucbefgartigimod weeklyiv time weeklynaiv weeklysc weekli self injectionsc weekli hr infusionfutur developmentsc weekli mliv everi weeksscsc monthli ivsc everi weekssc weekli hr infusionalexion momenta pharmaceut inc
momenta like show clinic meaning benefit mg
strh take data competitor give us confid momenta nipocalimab
though clinic data come pilot studi like
data replic two compani ucb argenx
believ underli biolog biomark data compani support biolog fcrn target
believ moa target fcrn valid ivig intraven immunoglobulin
plasmapheresi plasma exchange/ plex therapi current use treat patient
strh take ivig immedi act
therapi effect begin wear
day measur
later period day vs day
detect stat sig
anti-fcrn drug
compani report strh research
strh take ivig reduc serum igg
competit fcrn bind barth et al conclud ivig
plex compar clinic outcom mg patient notabl
abl detect addit benefit mg least qmg scale
fact plex slightli larger improv statist
plasmapheresi therapi reduc pathogen antibodi also
shown provid clinic benefit
page
strh take player indic myasthenia gravi mg believ whether indic
also pursu fcrn anoth mechan action momenta second product
could better ivig product less clear
momenta pursu
fcrn player go mg
fcrn player imvt also pursu itp
momenta pursu itp non-fcrn product could better ivig product
momenta fcrn player pursu hdfn
five fcrn player argx ucb pursu itp
momenta current pursu
argenx player
argenx ucb pursu
immunov player
compani report strh research
page
fcrn players- fcrn playersivigmg argx ucb imvt hdfnitpwaiha imvt pv argx cidp argx ucb go imvt itp argx ucb fcrn mnta-mntagener myasthenia gravi gmg primari immun thrombocytopenia itp pemphigu vulgari pv chronic inflammatori demyelin polyneuropathi cidp hemolyt diseas fetu newborn hdfn grave ophthalmopathi go warm autoimmun hemolyt anemia waiha inc
second indic hemolyt diseas fetu newborn hdfn
hdfn mother antibodi blood fetu due screen often dont know
caus anemia newborn often result death
would reduc mom antibodi toward fetu prevent anemia loss child could allow
mani women second children first children safe
hdfn allow momenta establish safe pregnant women becom main player
compani report strh research
page
momenta fcrn player go hdfn fda track
view approv hdfn would provid broader label inclus pregnant women
differenti fcrn competitor fetomatern diseas
compani report strh research
page
phase evalu nipocalimab hdfntoplin data
primari efficaci endpoint proport patient give live birth without iut
compani report strh research
page
design enrol patient treatment period
compani report strh research
page
data hdfn possibl launch els
success phase believ file data launch
chart outlin conserv timelin need expans trial would
launch
compani report strh research
page
third indic warm autoimmun hemolyt anemia waiha
rituximab label
compani report strh research
page
three fcrn compani waiha momenta lead
momenta lead waiha believ becom main player waiha opportun
file current studi
momenta expect present top-line phase data
momenta launch phase aug grant fda track design
immunov alexion also indic interest waiha
immunov expect file ind
alexion expect initi phase earli
compani report strh research
page
phase top-line phase dataalexion initi phase waihaimmunov file ind waihawaiha momenta pharmaceut inc
momenta trial design waiha
primari secondari waiha
primari endpoint patient clinic relev increas hemoglobin
secondari endpoint marker hemolysi fatigu
possibl pivot
interim analysi ia provid decis studi continu vs futil termin one
group studi termin result ia known momenta
page
potenti indic compani thought less like go
chronic inflammatori demyelin polyneuropathi cidp think best
idiopath thrombocytopen purpura momenta think better
hemolyt diseas fetu newborn hdfn
mani indic momenta go
page
next month catalyst rich fcrn space
compani report strh research
page
companydrugdrug classtarget patient top-line phase adapt initi phase registr initi phase phase poc kol event trial design cidpefgartigimod data path top-line data phase top-line data phase top-line data phase file ind initi phase sc small phase sad/mad biomark datawaihaearli initi phase initi phase mgtbdearli initi trial use sc top-line phase top-line phase initi trial top-line phase top-line phase vivacity-mg top-line phase updat sc formulationhuman fc fragmenthuman aglycosylatedalexion pharmaceuticalsmomentaargenximmunovantefgartigimod myasthenia gravi gmg immun thrombocytopen purpura itp pemphigu vulgari pv chronic inflammatori demyelin polyneuropathi cidp hemolyt diseas fetu newborn hdfn grave ophthalmopathi go warm autoimmun hemolyt anemia waiha determin tbd inc
street yet give credit potent ivig
page
possibl potent therapi autoimmun inflammatori diseas
immunodefici ivig use
collabor
potenti massiv upsid
compani report strh research
page
ivig product differ current ivig lot sialic acid igg momenta
develop target antibody-medi autoimmun diseas immun thrombocytopen purpura
itp see mani opportun go
sialyl
compani report strh research
momenta develop rigor quality-
control process hypersialyl igg
page
support unsupport research anti-inflammatori effect sialyl igg
need know
conflict report publish literatur
mechan known fulli understood
support
cell-independ vaccin result gener
group studi ivig protect fatal herp simplex viral
hypersialyl immunosuppress antibodi suffici inhibit
enceph report sialyl requir rather
cell activ pathogen immun reaction
induct regulatori cell
anthoni rm et al abl recapitul immunoinhibitori effect
ivig mous model rheumatoid arthriti use
increas sialyl fab fc region
improv rather abrog efficaci ivig itp mous
mous studi ivig demonstr sialyl igg fraction bind
mous express regulatori macrophag inhibitori
activ sialyl igg fraction vivo
group report use desialyl ivig itp model report
sialyl non-necessari
mechan sialyl fc type ii fcr dc-sign
sambucu nigra agglutinin -enrich ivig arthriti model
inhibitori type fc receptor fcriib function
report sialyl enhanc ivig activ
tandem carri model joint inflamm
engag type ii fcr regulatori macrophag
sialyl igg induc secret subsequ signal
basophil releas upregul express inhibitori
receptor fcriib effector inflammatori monocyt therebi
strh take believ support research suggest sialyl anti-
inflammatori properti non-support research view difficulti elucid anti-inflammatori
effect due lack robust protocol enrich low abund sialyl igg commonli use sambucu
page
momenta data support anti-inflammatori effect hypersialyl igg
strh take believ momenta data add support sialyl igg anti-inflammatori effect could
potent ivig therapi believ attract option patient itp await
confirmatori data give credit massiv upsid potenti work
potent
ivig
compani report strh research
page
help differenti momenta competitor indic
potenti
product better suit cidp
fcrn success itp
could easili translat
cidp
momenta go mg fcrn
nipocalimab mg
indic pursu fcrn
momenta go itp
competitor go
fcrn
compani report strh research
page
controversi whether fcrn ivig-lik therapi better suit itp
strh take biolog link itp inflamm support addit benefit ivig itp
rituximab label
momenta go itp
competitor go
fcrn
pathogen antibodi bind circul platelet lead
normal healthi rang platelets/l
platelets/l lead danger bleed
trauma
clinic trial use
/l standard threshold respons
increas risk spontan intern bleed
chronic itp affect patient us
itp close relat inflamm
inflamm trigger itp itp induc inflamm
ivig gammaplex approv itp
compani report strh research
page
fcrn player approv ivig itp help defin efficaci
data anti-fcrn drug argenx ucb still earli look effect
await data see compar ivig momenta
would want see respons platelets/l fcrn ivig see go high
durabl day common headach
concept itp therapi includ ivig see look effect fcrn
like auto antibodi compon could address
compani report strh research
page
number day clinic trialday platelet count std n/n percent subject platelet count ivig vs placebo vs placebo vs placebo least two vs placebonon drugsphas inc
phase trial immun thrombocytopen purpura itp
part a-c complet give us look itp ton may requir part
get better sens
conveni shorter infus
time smaller dose
look proof-of-
compani report strh research
page
catalystiniti drugsefgartigimod inc
file itp
compani report strh research
page
collabor earli
collabor
potenti massiv upsid
compani report strh research
page
phase healthi volunt develop
lead candid sifbodi select immunomodul fc receptor platform
lead candid sifbodi select immunomodul fc receptor platform
fc trimer
phase studi healthi volunt commenc
momenta grant exclus world-wide licens behr -au nr wholly-own indirect
subsidiari limit research develop manufactur commerci research
fc multim licens option agreement grant momenta februari
momenta split global research develop cost profit us
momenta entitl sales-bas royalti payment mid-singl low-doubl digit percentag momenta
also entitl mn mileston payment
page
fc receptor interact igg antibodi fc fragment
strh take fc fragment
immun cell via fc receptor
result differ outcom
balanc interact
ultim help modul drive
fc receptor allow fine tune
immun respons help
autoimmun inflammatori
page
sifbodi select immunomodul fc receptor platform tri inhibit immun
system might autoimmun diseas
sifbodi platform produc igg fc multim specif interact immun system fc signal
bindingallow fine tune immun respons
goal develop fc multim
creat differenti therapi ivig
fcrn focus modul
compani report strh research
page
proof-of-concept sifbodi platform
strh take see proof concept sif bodi platform
approv antibodi util fcr
three approv antibodi use fcr function
sifbodi abl target darzalex-resist mm
anti-ctla sifbodi enhanc kill cancer treg cell
compani report strh research
page
platelet count back
normal
efficaci ivig
look
efficaci ivig
third dose
seem
efficaci slightli
better ivig
dose
show efficaci mice model
autoimmune/inflammatori diseas
equival better ivig
almost fulli rescu itp mice
better ivig arthriti third dose
equal better ivig
compani report strh research
page
momenta share cost profit
respons commerci
collabor
biosimilar eylea
current pivot trial diabet macular edema
project launch sale
random double-blind control multi-cent studi eylea
sandoz collabor glatopa
glatopa gener version copaxon
gener version once-daili copaxon weekli copaxon
sandoz novn-ch nr respons commerci
project quarterli sale mn annual declin sale
glatopa face continu aggress competit
page
manag compens
page
manag team bring wealth experi knowledg
mr wheeler join momenta ceo septemb led compani launch first
complex drug product includ first gener version lovenox once-daili copaxon
 entrepreneur year region award winner
may boston globe name momenta number one compani annual globe survey top
prior presid chiron spent year chiron
prior senior member boston consult group health care practic work extens health
prior vice-president oncolog financ baxalta
prior head plan ironwood pharmaceut
ms robertson join momenta may svp becam cfo oct
dr arroyo join momenta june
prior
prior
prior area head neurosci bristol-my squibb neurolog global area head
eisai global clinic develop
dr arroyo receiv md autonom univers madrid phd univers barcelona
dr man join momenta januari
prior vice-president head immunolog research biogen idec
prior vice-president global head inflamm autoimmun transplant research roch
dr man hold phd univers otago new zealand
dr kwon join momenta januari
prior senior director bd biogen idec
prior experi advanc technolog ventur
page
manag compens align well sharehold interest
valuat base aggreg grant date fair valu option restrict stock unit award grant comput accord account standard board
fasb account standard codif topic stock compens exclud effect estim forfeitur aggreg grant date fair valu option restrict stock
unit award correspond actual valu realiz name execut upon vest exercis award assumpt use us respect valuat
option restrict stock unit award set forth note note financi statement contain annual report year end decemb file
secur exchang commiss februari amount includ stock award column respect psu grant reflect estim
probabl outcom perform condit grant date award determin fasb topic
includ match park transit gym fee
overal compens plan appear line sharehold interest name execut offic
elig earn incent bonu base individu perform goal well corpor goal
relat product develop advanc clinic studi compens
execut structur around achiev corpor goal mileston year
base subject object perform goal determin board director
page
page
pt deriv probabl adjust dcf
use discount rate believ reflect risk smid-cap biotech
appli probabl three market equat adjust sale mg
waiha hdfn account think investor assign valu
see initi data phase await poc data
use typic valu post smaller phase trial mg waiha read hdfn
post posit poc data
figur million dollar except per share data
compani report strh research
page
assumpt sale sale free projectionsgaap ebit stock base depreci work capit capit free valu growth rate valu valu outstand valu per valu per inc
risk valuat
clinic trial failur poor side effect profil addit data come lead asset
two studi proof concept studi believ current share
price success least
financ risk compani cash runway like need rais money soon
could depend market condit
emerg profil fcrn class clinic trial failur argenx mg stock could
pressur howev think momenta fcrn better competit
competit fcrn landscap competit momenta behind vs first gener compound
page
inc oper biotechnolog compani focus discoveri
develop novel biolog therapi treatment rare immune-medi diseas
product includ glatiram acet inject enoxaparin sodium inject compani
found ram sasisekharan paul schimmel ganesh venkatraman kaundinya may
headquart cambridg
like momenta expertis fc modif focu rare immune-medi diseas
develop anti-fcrn molecul would potenti displac ivig use treat mani
autoimmun diseas ivig market current suppli often constrain ivig therapi
requir multi-day infus ivig short iv sc believ
potenti take chunk sale fcrn biolog make sens could
address remain popul multipl readout drug expect next
compani two key drug develop could drive upsid anti-fcrn drug
hypersialyl ivig product
evalu fcrn landscap deep-div conclud momenta like
potent fcrn therapi greatest reduct igg lower dose believ could
translat better effiaci smaller volum iv sc form
believ data two indic third could increas probabl
investor assign franchis clariti also come sub-cutan version may
learn conveni patient
see market opportun model adjust sale
account earli stage estim everi addit billion sale could worth
share depend time
momenta may first market warm autoimmun hemolyt anemia waiha may
anti-fcrn drug label pregnant women provid broader label opportun
sole fcrn player fetomatern space studi hdfn could allow file
believ momenta approach develop molecul fcrn ivig space uniqu first
creat molecul characterist want other average licens
also chose indic first look biolog may give advantag
hypersialyt igg molecul bn upsid potenti bn ivig
market potent ivig molecul could address indic fcrn
ivig market label first indic itp fcrn look effect ivig
expect data also easier manufactur vs ivig
valuat risk
pt deriv probabl adjust dcf discount rate termin growth
rate believ discount rate appropri risk associ smid-cap biotech
appli probabl account success expect
account posit poc
risk rate price target includ financ risk clinic trial failur competit
page
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
